Original Article
Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both
N Engl J Med 2005; 352:2581-2588June 23, 2005
- Abstract
Background
The risk of sudden death from cardiac causes is increased among survivors of acute myocardial infarction with reduced left ventricular systolic function. We assessed the risk and time course of sudden death in high-risk patients after myocardial infarction.
Methods
We studied 14,609 patients with left ventricular dysfunction, heart failure, or both after myocardial infarction to assess the incidence and timing of sudden unexpected death or cardiac arrest with resuscitation in relation to the left ventricular ejection fraction.
Results
Of 14,609 patients, 1067 (7 percent) had an event a median of 180 days after myocardial infarction: 903 died suddenly, and 164 were resuscitated after cardiac arrest. The risk was highest in the first 30 days after myocardial infarction — 1.4 percent per month (95 percent confidence interval, 1.2 to 1.6 percent) — and decreased to 0.14 percent per month (95 percent confidence interval, 0.11 to 0.18 percent) after 2 years. Patients with a left ventricular ejection fraction of 30 percent or less were at highest risk in this early period (rate, 2.3 percent per month; 95 percent confidence interval, 1.8 to 2.8 percent). Nineteen percent of all sudden deaths or episodes of cardiac arrest with resuscitation occurred within the first 30 days after myocardial infarction, and 83 percent of all patients who died suddenly in the first 30 days did so after hospital discharge. Each decrease of 5 percentage points in the left ventricular ejection fraction was associated with a 21 percent adjusted increase in the risk of sudden death or cardiac arrest with resuscitation in the first 30 days.
Conclusions
The risk of sudden death is highest in the first 30 days after myocardial infarction among patients with left ventricular dysfunction, heart failure, or both. Thus, earlier implementation of strategies for preventing sudden death may be warranted in selected patients.
Media in This Article
Figure 1
Kaplan–Meier Estimates of the Rates of Sudden Death or Cardiac Arrest with Resuscitation, According to the Left Ventricular Ejection Fraction (LVEF).Figure 2
Rate of Sudden Death or Cardiac Arrest with Resuscitation over the Course of the Trial in the Three Categories of Left Ventricular Ejection Fraction (LVEF).Article Activity
- Article
Sudden death is a catastrophic complication of acute myocardial infarction.1 Although many patients who die from an acute myocardial infarction do so before reaching the hospital, those admitted remain at substantial risk for ventricular arrhythmias. That risk is greatest in the first few hours, declines rapidly thereafter, and is influenced by the extent of myocardial injury, recurrent ischemia, electrolyte abnormalities, and other factors.2,3 The success of coronary care units in the 1960s was, in part, related to the early identification and treatment of life-threatening arrhythmias that occurred in the setting of an acute myocardial infarction. Though the risk of sudden death is believed to decrease rapidly after infarction, the extent and time course of this change in risk have not been well studied, especially since the use of coronary reperfusion, beta-blockers, and angiotensin-converting–enzyme inhibitors has become widespread.
Reduced left ventricular function is a major risk factor for death, including sudden death, after myocardial infarction.4,5 This observation has led to trials of implantable cardioverter–defibrillators (ICDs) in patients with a low left ventricular ejection fraction after infarction.6 The Multicenter Unsustained Tachycardia Trial (MUSTT) demonstrated the benefit of an ICD in patients with coronary artery disease, a left ventricular ejection fraction of 40 percent or less, and inducible sustained ventricular tachycardia.7 The Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II)8 further showed a benefit of empirical ICD therapy in patients with a left ventricular ejection fraction of 30 percent or less one month or more after myocardial infarction. Although these studies enrolled few patients within six months after they had had a myocardial infarction, the results are reflected in the current American College of Cardiology–American Heart Association guidelines for the management of acute myocardial infarction,9 which recommend the implantation of an ICD one month or more after myocardial infarction in patients with a left ventricular ejection fraction of 30 percent or less and in those with a left ventricular ejection fraction of 40 percent or less and additional evidence of electrical instability. In contrast, the recently reported Defibrillator in Acute Myocardial Infarction Trial (DINAMIT)10 did not show that the implantation of an ICD 6 to 40 days after myocardial infarction reduced the risk of death in patients with a left ventricular ejection fraction of 35 percent or less and reduced heart-rate variability. Nevertheless, the risk of sudden death in the early period after myocardial infarction remains high and has not been well studied in the modern era.11 To better delineate the early and later risk of sudden death after myocardial infarction and the association of these risks with the left ventricular ejection fraction, we studied patients enrolled in the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Methods
VALIANT was a randomized, controlled trial of treatment with valsartan, captopril, or both in 14,703 patients with a first or subsequent acute myocardial infarction complicated by heart failure, left ventricular systolic dysfunction, or both.12 Patients were enrolled between December 1998 and June 2001. All patients had an ejection fraction of no more than 40 percent or clinical or radiologic evidence of heart failure complicating their myocardial infarction. For this analysis, we excluded 94 patients because they had already received an ICD before randomization. All patients gave written informed consent, and the research protocol was approved by the appropriate review boards. The details of the patient population and the protocol, including inclusion and exclusion criteria, have been reported previously.12
A central adjudication committee reviewed all deaths and episodes of cardiac arrest with resuscitation in a blinded fashion, using source documentation provided by the site investigators. Deaths were classified as having cardiovascular or noncardiovascular causes, and deaths from cardiovascular causes were further classified as sudden or due to myocardial infarction, heart failure, stroke, or another cardiovascular cause. Sudden death was explicitly defined as death that occurred “suddenly and unexpectedly” in a patient in otherwise stable condition and included witnessed deaths (with or without documentation of arrhythmia) and unwitnessed deaths if the patient had been seen within 24 hours before death but had not had premonitory heart failure, myocardial infarction, or another clear cause of death. Cardiac arrest with resuscitation was defined as cardiac arrest from which a patient regained consciousness and subsequent cognitive function, even briefly.
The median duration of follow-up was 24.7 months. Sudden deaths and episodes of cardiac arrest with resuscitation were combined for this analysis. The left ventricular ejection fraction was determined before randomization (a median of five days after myocardial infarction) at the clinical site in 11,256 patients: echocardiography was used in 9095, radionuclide ventriculography in 272, and contrast ventriculography in 1889. The analysis of the incidence and timing of sudden death included all patients and was related to the left ventricular ejection fraction in the subgroup of patients for whom information on the ejection fraction was available: 3852 with an ejection fraction of 30 percent or less, 4998 with an ejection fraction of 31 to 40 percent, and 2406 with an ejection fraction of more than 40 percent.
The rates of sudden death were assessed by dividing the events in each period by the number of person-days of exposure and are expressed as the percentage per month. Baseline clinical characteristics were compared with the use of Student's t-test for continuous variables and the chi-square test for categorical variables. The risk of sudden death associated with each decrease of 5 percentage points in the left ventricular ejection fraction was assessed in a Cox proportional-hazards model, with adjustment for all known baseline covariates.
Results
Of 14,609 patients, 1067 (7 percent) had an event: 903 patients died suddenly, and 164 were resuscitated after cardiac arrest. For 643 of the 1067 patients (60 percent), this was the first cardiovascular event after enrollment. Five patients who were resuscitated after cardiac arrest died on the day of resuscitation. The median time to sudden death or cardiac arrest with resuscitation was 180 days after myocardial infarction (interquartile range, 50 to 428). Of the 164 patients who were resuscitated, 108 (66 percent) were alive at six months and 93 (57 percent) were alive at the end of the trial. As compared with surviving patients without events, patients who died suddenly or had cardiac arrest with resuscitation were significantly older; had higher baseline systolic and diastolic blood pressures, baseline heart rate, and Killip class; had a lower left ventricular ejection fraction; were more likely to have a history of diabetes or hypertension; and were less likely to have been treated with reperfusion therapy, amiodarone, or beta-blockers (Table 1Table 1
Baseline Characteristics of the Patients, According to the Outcome.). The differences between patients who died suddenly or were resuscitated after cardiac arrest and those who died of other causes were much less clinically apparent.During the first 30 days after myocardial infarction, 126 patients died suddenly and 72 patients were resuscitated after cardiac arrest (representing 19 percent of all patients with such events during the trial), for an event rate of 1.4 percent per month (95 percent confidence interval, 1.2 to 1.6 percent). Eighty-three percent of sudden-death events from which the patients were not resuscitated occurred after hospital discharge. Of the patients who were resuscitated during the first 30 days after myocardial infarction, 74 percent were alive at 1 year. Event rates and the cumulative incidence of events during various periods in the study are shown in Table 2Table 2
Event Rate and Cumulative Incidence of Events during Follow-up.. The rate of sudden death or cardiac arrest with resuscitation decreased precipitously during the first year, declining to 0.14 percent per month (95 percent confidence interval, 0.11 to 0.18 percent) after year 2.Figure 1Figure 1
Kaplan–Meier Estimates of the Rates of Sudden Death or Cardiac Arrest with Resuscitation, According to the Left Ventricular Ejection Fraction (LVEF). shows the Kaplan–Meier estimates of the rate of sudden death or cardiac arrest with resuscitation according to the left ventricular ejection fraction in patients in whom the ejection fraction was measured. The increased early incidence of these events was most apparent among patients with an ejection fraction of 30 percent or less: the incidence rate during the first 30 days was 2.3 percent per month (95 percent confidence interval, 1.8 to 2.8 percent) (Figure 1 and Figure 2Figure 2Rate of Sudden Death or Cardiac Arrest with Resuscitation over the Course of the Trial in the Three Categories of Left Ventricular Ejection Fraction (LVEF).). Of the 156 sudden deaths or episodes of cardiac arrest with resuscitation that occurred during the first 30 days, 85 occurred among the 3852 patients with an ejection fraction of 30 percent or less (54 percent; 1 percent of all patients with a known left ventricular ejection fraction). Of the 3852 patients with an ejection fraction of 30 percent or less, 399 (10 percent) died suddenly or had cardiac arrest with resuscitation during the trial, as compared with 295 of the 4998 patients with an ejection fraction of 31 to 40 percent (6 percent) and 119 of the 2406 patients with an ejection fraction of more than 40 percent (5 percent). Among the patients with a known left ventricular ejection fraction, 49 percent of all sudden deaths or cardiac arrests with resuscitation occurred in patients with an ejection fraction of 30 percent or less, and this proportion remained relatively constant throughout follow-up.Among the 399 patients with an ejection fraction of 30 percent or less who died suddenly or had cardiac arrest with resuscitation, 85 (21 percent) did so during the first 30 days after myocardial infarction, as compared with 50 of 295 such patients with an ejection fraction of 31 to 40 percent (17 percent) and 21 of 119 such patients with an ejection fraction of more than 40 percent (18 percent). Nevertheless, even among patients with an ejection fraction of more than 40 percent, the rate of sudden death or cardiac arrest with resuscitation was more than six times as high in the first month as after one year. Although the incidence of sudden death or cardiac arrest with resuscitation declined markedly over time in all groups, the relative risk of these events remained two to three times as high as among patients with a left ventricular ejection fraction of 30 percent or less as among patients with an ejection fraction of more than 40 percent, although overall, the absolute rate after two years was substantially lower than during the early period. When the left ventricular ejection fraction was considered as a continuous variable, each decrease of 5 percentage points in the ejection fraction was associated with a 21 percent increase in the risk of sudden death or cardiac arrest with resuscitation during the first 30 days after myocardial infarction (hazard ratio, 1.21; 95 percent confidence interval, 1.10 to 1.30), after adjustment for all known baseline covariates.
Discussion
The results of our analysis confirm that patients with left ventricular dysfunction, heart failure, or both after myocardial infarction are at high risk for sudden death or cardiac arrest with resuscitation. The absolute risk is greatest in the early period after myocardial infarction and among patients with the lowest ejection fraction and declines significantly over time, reaching a steady state at approximately one year. The risk was increased despite the fact that all patients, according to the study design, were receiving inhibitors of the renin–angiotensin system and the majority were receiving beta-blockers and aspirin.
Several measures may identify patients at highest risk for sudden death in the first year after myocardial infarction.3,13,14 These are an assessment of the frequency or severity of arrhythmia, including the incidence of premature ventricular contractions, nonsustained ventricular tachycardia, dispersion of the QT interval, and late potentials on signal-averaged electrocardiograms; measures of autonomic function; and the results of invasive electrophysiological testing.15-17 The left ventricular ejection fraction, an independent risk factor for sudden death, is currently the most widely used and robust clinical determinant of risk after infarction and has become the basis for determining a patient's eligibility for ICD therapy.9 However, it is poor at distinguishing between patients who will die from arrhythmia and those who will die of other cardiovascular causes.18 In VALIANT, patients who died suddenly were similar to those who died of other causes. Other causes of death included pump failure, recurrent myocardial infarction, procedure-related causes, other cardiac causes, and noncardiac causes, which were relatively rare in this population. Baseline characteristics that were associated with an increased risk of death from other causes were also associated with an increased risk of sudden death. Our inability to distinguish patients who died suddenly from those who died of other causes may reflect our lack of more sophisticated measures of the risk of arrhythmia in this study.
The other key determinant of the risk of sudden death is the time after myocardial infarction. The absolute risk of sudden death is highest in the first year after myocardial infarction. Our data suggest that this risk is greatest within the first week after myocardial infarction and falls rapidly within the first month. The increased early rate of sudden death was highest among patients with the lowest left ventricular ejection fraction, but the high incidence was not restricted to patients with the lowest left ventricular ejection fraction. Indeed, the incidence of sudden death in the group with the highest ejection fraction was greater in the first 30 days than was the incidence of sudden death in the group with the lowest ejection fraction after 90 days. Moreover, patients who died suddenly or had cardiac arrest with resuscitation were in clinically stable condition and many had recently been discharged from the hospital. Thus, to prevent sudden death after infarction, the ideal strategy must also take into account patients with a better-preserved left ventricular ejection fraction (more than 40 percent).
The discriminatory effect of the left ventricular ejection fraction appears to be greatest in the first six months after myocardial infarction. Among patients who survived beyond one year, the annualized rate of sudden death was still highest in the group with the lowest left ventricular ejection fraction but was fairly similar among the three ejection-fraction groups, although the relative risk remained higher in the groups with a lower ejection fraction. This observation, however, should be tempered by the fact that patients who survive are already at lower risk. Also, ventricular function was measured relatively early after infarction, and in some patients, substantial recovery of ventricular function may have occurred with a concomitant decrease in the risk of sudden death. An additional decline in the left ventricular ejection fraction may occur over time, and the risk of sudden death at a particular time after myocardial infarction is more likely to be related to the ejection fraction at that time than to the ejection fraction in the periinfarction period.
Although our findings suggest that a strategy of treating a greater proportion of patients early and focusing on those with a low left ventricular ejection fraction later might be the most efficient approach to minimizing the risk of sudden death after myocardial infarction, the recently reported DINAMIT showed no benefit of implanting an ICD 6 to 40 days after myocardial infarction in patients with an ejection fraction of 35 percent or less and evidence of reduced heart-rate variability.10 Indeed, in that trial, a decrease in the rate of death from arrhythmia was offset by an increase in the rate of death from other causes.19 The DINAMIT findings thus did not provide support for the use of early ICD therapy in a high-risk population after myocardial infarction and underscore the fact that patients at increased risk for sudden death from arrhythmia are also at increased risk for death from other causes.
Although it is difficult to reconcile the absence of a benefit in DINAMIT with the substantially increased risk of sudden death we observed in the early post-infarction period, there were a number of important differences between the two studies. Although DINAMIT enrolled patients with a lower overall left ventricular ejection fraction than did VALIANT, the average time to enrollment was 18 days after myocardial infarction — 13 days later than the average enrollment date in VALIANT — and thus, DINAMIT may have selected for patients already at lower risk for sudden death. Moreover, at 7.2 percent per year, the overall mortality rate was lower in DINAMIT than in VALIANT. Although the rate of death from arrhythmia in the DINAMIT control group was similar to the rate of sudden death in VALIANT (3.5 percent and 3.7 percent per year, respectively), the true rate of death from arrhythmia in our study may have been much higher, since only unexpected deaths were categorized as sudden, thereby excluding patients with fatal arrhythmia in the setting of myocardial infarction or pump failure. Alternatively, DINAMIT, with only 120 deaths, may have been statistically underpowered to demonstrate a clinically important difference between groups, an interpretation that would suggest the need for additional studies of ways to prevent sudden death from arrhythmia in the early period after infarction.
It remains unclear whether therapies targeted at a high-risk population soon after infarction would reduce the risk of sudden unexpected death, but our data provide a rationale for considering early-intervention strategies, including short-term therapies, in selected patients at risk. This is supported by the fact that the majority of our patients (74 percent) who were resuscitated during the first 30 days were alive at 1 year. In addition, although our data suggest that the overall risk of sudden death or cardiac arrest with resuscitation increases with a decreasing left ventricular ejection fraction, even in patients with an ejection fraction of more than 40 percent, the risk of sudden death or cardiac arrest with resuscitation was six times as high in the first 30 days as at 1 year, suggesting a potential role for early short-term intervention, even in lower-risk patients. For example, if all sudden deaths could be prevented, a strategy of treating everyone for 30 days and only those with a left ventricular ejection fraction of 30 percent or less beyond 30 days in the VALIANT study would potentially have prevented or postponed 507 deaths, as compared with 317 deaths with the use of the currently recommended strategy of treating only those with an ejection fraction of 30 percent or less beyond 30 days. This approach may not be practical on the basis of current ICD technology, but such an approach might be practical and cost-effective in the future, although it must be noted that current Medicare regulations do not allow for payment for ICD therapy before 40 days after myocardial infarction.6
A number of limitations of this analysis should be noted. First, the left ventricular ejection fraction was measured locally, not centrally, although local estimation of the ejection fraction is used to make clinical decisions. Second, some patients identified as having died suddenly may have died from causes such as aortic dissection, pulmonary embolism, stroke, and especially, reinfarction; in the case of reinfarction, sudden death may still be due to arrhythmia.20 Also, since our definition of sudden death specified prior stability, we may have excluded many deaths from arrhythmia that occurred in the setting of myocardial infarction or heart failure. Finally, although our data may help guide interventional strategies that reduce risk, we did not assess the efficacy of such strategies.
In summary, we demonstrated that the risk of sudden death is highest soon after myocardial infarction — particularly during the first 30 days. This risk is greatest among patients with the lowest left ventricular ejection fraction (30 percent or less), but even patients with a high ejection fraction (more than 40 percent) are at substantially increased risk in the early post-infarction period, as compared with the subsequent risk, and the discriminatory effect of the left ventricular ejection fraction declines over time. Although it is not known whether early ICD therapy would reduce these risks, taken in the context of recent data demonstrating the benefits of ICD therapy in high-risk patients,21 our data suggest the need to consider implementing strategies to prevent sudden death in selected patients before the time recommended by current guidelines.
Supported by a grant from Novartis Pharmaceuticals.
Source Information
From the Cardiovascular Division, Brigham and Women's Hospital, Boston (S.D.S., P.V.F., M.A.P.); Novartis Pharmaceuticals, East Hanover, N.J. (S.Z.); the Department of Cardiology, Western Infirmary, Glasgow, Scotland (J.J.V.M.); Duke University Medical Center, Durham, N.C. (E.V., K.P., R.M.C.); University of Wurzburg, Wurzburg, Germany (G.E.); the National Center for Health Services, Budapest, Hungary (A.H.); the University of Montreal, Montreal Heart Institute, Montreal (J.L.R.); Associazione Nazionale Medici Cardiologi Ospedalieri Research Center, Florence, Italy (A.M.); the Department of Cardiology, Rigshospitalet, Copenhagen (L.K.); the Department of Cardiology, Green Lane Hospital, Auckland, New Zealand (H.W.); and Leuven Coordinating Center, Leuven, Belgium (F.V.W.).
Address reprint requests to Dr. Solomon at the Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, or at ssolomon@rics.bwh.harvard.edu.
- References
References
1
Huikuri HV ,Castellanos A ,Myerburg RJ . Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345:1473-1482
Full Text | Web of Science | Medline2
Savard P ,Rouleau JL ,Ferguson J , et al. Risk stratification after myocardial infarction using signal-averaged electrocardiographic criteria adjusted for sex, age, and myocardial infarction location. Circulation 1997;96:202-213
Web of Science | Medline3
Zipes DP ,Wellens HJ . Sudden cardiac death. Circulation 1998;98:2334-2351
Web of Science | Medline4
The Multicenter Postinfarction Research Group
Full Text | Web of Science | Medline5
Mukharji RJ ,Rude RE ,Poole WK , et al. Risk factors for sudden death after acute myocardial infarction: two year follow-up. Am J Cardiol 1984;54:31-36
CrossRef | Web of Science | Medline6
Al-Khatib SM, Sanders GD, Mark DB, et al. Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. Am Heart J (in press).
7
Buxton AE ,Lee KL ,Fisher JD ,Josephson ME ,Prystowsky EN ,Hafley G . A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999;341:1882-1890[Erratum, N Engl J Med 2000;342:1300.]
Full Text | Web of Science | Medline8
Moss AJ ,Zareba W ,Hall WJ , et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-883
Full Text | Web of Science | Medline9
Antman EM ,Anbe DT ,Armstrong PW , et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004;110:e82-e292
CrossRef | Medline10
Hohnloser SH ,Kuck KH ,Dorian P , et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004;351:2481-2488
Full Text | Web of Science | Medline11
Huikuri HV ,Tapanainen JM ,Lindgren K , et al. Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era. J Am Coll Cardiol 2003;42:652-658
CrossRef | Web of Science | Medline12
Pfeffer MA ,McMurray JJ ,Velazquez EJ , et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906[Erratum, N Engl J Med 2004;350:203.]
Full Text | Web of Science | Medline13
Califf RM ,McKinnis RA ,Burks J , et al. Prognostic implications of ventricular arrhythmias during 24 hour ambulatory monitoring in patients undergoing cardiac catheterization for coronary artery disease. Am J Cardiol 1982;50:23-31
CrossRef | Web of Science | Medline14
Myerburg RJ ,Kessler KM ,Castellanos A . Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med 1993;119:1187-1197
Web of Science | Medline15
Naccarella F ,Lepera G ,Rolli A . Arrhythmic risk stratification of post-myocardial infarction patients. Curr Opin Cardiol 2000;15:1-6
CrossRef | Web of Science | Medline16
Steinberg JS ,Regan A ,Sciacca RR ,Bigger JT Jr ,Fleiss JL . Predicting arrhythmic events after acute myocardial infarction using the signal-averaged electrocardiogram. Am J Cardiol 1992;69:13-21
CrossRef | Web of Science | Medline17
Kleiger RE ,Miller JP ,Bigger JT Jr ,Moss AJ . Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256-262
CrossRef | Web of Science | Medline18
Every N ,Hallstrom A ,McDonald KM , et al. Risk of sudden versus nonsudden cardiac death in patients with coronary artery disease. Am Heart J 2002;144:390-396
CrossRef | Web of Science | Medline19
Hohnloser SH ,Connolly SJ ,Kuck KH , et al. The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT): study protocol. Am Heart J 2000;140:735-739
CrossRef | Web of Science | Medline20
Uretsky BF ,Thygesen K ,Armstrong PW , et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial. Circulation 2000;102:611-616
Web of Science | Medline21
Bardy GH ,Lee KL ,Mark DB , et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-237
Full Text | Web of Science | Medline
- Citing Articles (154)
Citing Articles
1
Meghana R. Gaiki, Maria V. DeVita, Michael F. Michelis, Georgia Panagopoulos, Jordan L. Rosenstock. (2012) Troponin I as a prognostic marker of cardiac events in asymptomatic hemodialysis patients using a sensitive troponin I assay. International Urology and Nephrology
CrossRef2
D. G. Katritsis, M. E. Josephson. (2012) Sudden cardiac death and implantable cardioverter defibrillators: two modern epidemics?. Europace
CrossRef3
Hou Yu, Fang Pi-hua, Wu Yuan, Li Xiao-feng, Liu Jun, Li Zhi, Lei Sen, Shu Zhang. (2012) Prediction of sudden cardiac death in patients after acute myocardial infarction using T-wave alternans: a prospective study. Journal of Electrocardiology 45:1, 60-65
CrossRef4
Przemyslaw Guzik, Jaroslaw Piskorski, Petra Barthel, Axel Bauer, Alexander Müller, Nadine Junk, Kurt Ulm, Marek Malik, Georg Schmidt. (2012) Heart rate deceleration runs for postinfarction risk prediction. Journal of Electrocardiology 45:1, 70-76
CrossRef5
Christian Jons, Poul Erik Bloch Thomsen. (2011) Treating Cardiac Arrhythmias Detected With an Implantable Cardiac Monitor in Patients After an Acute Myocardial Infarction. Current Treatment Options in Cardiovascular Medicine
CrossRef6
Krishnakumar Nair, Jack V. Tu, Douglas S. Lee. (2011) Why Are Implantable Cardioverter Defibrillator Outcomes in Practice Different from Clinical Trials?. Cardiac Electrophysiology Clinics 3:4, 511-520
CrossRef7
Rajesh N. Subbiah, Peter Leong-Sit, Lorne J. Gula, Allan C. Skanes, James A. White, Raymond Yee, George J. Klein, Andrew D. Krahn. (2011) Evaluation of the Young Patient Resuscitated from Ventricular Fibrillation. Cardiac Electrophysiology Clinics 3:4, 593-608
CrossRef8
Stavros E. Mountantonakis, Mathew D. Hutchinson. (2011) Indications for Implantable Cardioverter-Defibrillator Placement in Ischemic Cardiomyopathy and after Myocardial Infarction. Current Heart Failure Reports 8:4, 252-259
CrossRef9
, E. Imai, J. C. N. Chan, S. Ito, T. Yamasaki, F. Kobayashi, M. Haneda, H. Makino. (2011) Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 54:12, 2978-2986
CrossRef10
Farzin Beygui, Jean-Philippe Labbé, Guillaume Cayla, Pierre-Vladimir Ennezat, Pascal Motreff, François Roubille, Johanne Silvain, Olivier Barthélémy, Nicolas Delarche, Eric Van Belle, Jean-Philippe Collet, Gilles Montalescot. (2011) Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life-threatening ventricular arrhythmia. International Journal of Cardiology
CrossRef11
L. Paranskaya, I. Akin, T. Chatterjee, A. Ritz, P. Paranski, T. Rehders, H. Ince, H. Schneider, C.A. Nienaber, D. Bänsch. (2011) Ventricular tachycardia and sudden death after primary PCI-reperfusion therapy. Herzschrittmachertherapie + Elektrophysiologie
CrossRef12
J. Sjoblom, L. Ljung, M. Frick, M. Rosenqvist, V. Frykman. (2011) Primary prevention of defibrillator implantation after myocardial infarction: clinical practice and compliance to guidelines. Europace
CrossRef13
M. Albaghdadi, M. Gheorghiade, B. Pitt. (2011) Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes. European Heart Journal 32:21, 2626-2633
CrossRef14
Barak Pertzov, Victor Novack, Doron Zahger, Amos Katz, Guy Amit. (2011) Insufficient compliance with current implantable cardioverter defibrillator (ICD) therapy guidelines in post myocardial infarction patients is associated with increased mortality. International Journal of Cardiology
CrossRef15
Darshan Dalal, Jonas de Jong, Fleur V.Y. Tjong, Yaping Wang, Nienke Bruinsma, Lukas Dekker, Arthur A.M. Wilde. (2011) Mild to moderate kidney dysfunction and the risk of sudden cardiac death in the setting of acute myocardial infarction. Heart Rhythm
CrossRef16
Colin J. Petrie, Adriaan A. Voors, Michele Robertson, Dirk J. Veldhuisen, Henry J. Dargie. (2011) A low pulse pressure predicts mortality in subjects with heart failure after an acute myocardial infarction: a post-hoc analysis of the CAPRICORN study. Clinical Research in Cardiology
CrossRef17
Samir Saba. (2011) Death during acute myocardial infarction: Dodging the first bullet. Heart Rhythm 8:9, 1467-1468
CrossRef18
Audrey L. Blewer, Marion Leary, Christopher S. Decker, James C. Andersen, Amanda C. Fredericks, Bentley J. Bobrow, Benjamin S. Abella. (2011) Cardiopulmonary resuscitation training of family members before hospital discharge using video self-instruction: A feasibility trial. Journal of Hospital Medicine 6:7, 428-432
CrossRef19
Richard L. Verrier, Thomas Klingenheben, Marek Malik, Nabil El-Sherif, Derek V. Exner, Stefan H. Hohnloser, Takanori Ikeda, Juan Pablo Martínez, Sanjiv M. Narayan, Tuomo Nieminen, David S. Rosenbaum. (2011) Microvolt T-Wave Alternans. Journal of the American College of Cardiology 58:13, 1309-1324
CrossRef20
Thomas A. Dewland, Jeffrey E. Olgin, Byron K. Lee. (2011) Indications for a Wearable Cardioverter-Defibrillator. Cardiac Electrophysiology Clinics 3:3, 339-347
CrossRef21
Eric C. Stecker, Sumeet S. Chugh. (2011) Prediction of sudden cardiac death: next steps in pursuit of effective methodology. Journal of Interventional Cardiac Electrophysiology 31:2, 101-107
CrossRef22
Johannes Holzmeister, Christophe Leclercq. (2011) Implantable cardioverter defibrillators and cardiac resynchronisation therapy. The Lancet 378:9792, 722-730
CrossRef23
L.Y. Eun, H. Song, E. Choi, T.G. Lee, D.W. Moon, D. Hwang, K.H. Byun, J.H. Sul, K.C. Hwang. (2011) Implanted bone marrow-derived mesenchymal stem cells fail to metabolically stabilize or recover electromechanical function in infarcted hearts. Tissue and Cell 43:4, 238-245
CrossRef24
Vincent Floré, Piet Claus, Gudrun Antoons, Peter Oosterhoff, Patricia Holemans, Marc A. Vos, Karin R. Sipido, Rik Willems. (2011) Microvolt T-wave alternans and beat-to-beat variability of repolarization during early postischemic remodeling in a pig heart. Heart Rhythm 8:7, 1050-1057
CrossRef25
N. A. Mark Estes, Munther Homoud, Jonathan Weinstock, Caroline Foote, Ania Garlitski, Mark Link, Afshin Ehsan. (2011) Interdisciplinary strategies for arrhythmia program development: measuring quality, performance, and outcomes. Journal of Interventional Cardiac Electrophysiology 31:1, 91-99
CrossRef26
Sabha Bhatti, Abdul Hakeem, Mian Atif Yousuf, Hussein R. Al-Khalidi, Wojciech Mazur, Yukitaka Shizukuda. (2011) Diagnostic performance of computed tomography angiography for differentiating ischemic vs nonischemic cardiomyopathy. Journal of Nuclear Cardiology 18:3, 407-420
CrossRef27
Andrea M. Russo. (2011) Risk stratification early post-MI after percutaneous coronary intervention: Should programmed ventricular stimulation be revisited?. Heart Rhythm 8:4, 500-502
CrossRef28
Samir Saba. (2011) Sudden Cardiac Death Risk Stratification and Assessment: Primary Prevention Based on Ejection Fraction Criteria. Heart Failure Clinics 7:2, 175-183
CrossRef29
Saurabh Kumar, Gopal Sivagangabalan, Aravinda Thiagalingam, Elizabeth B. West, Arun Narayan, Norman Sadick, Andrew T.L. Ong, Pramesh Kovoor. (2011) Effect of reperfusion time on inducible ventricular tachycardia early and spontaneous ventricular arrhythmias late after ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart Rhythm 8:4, 493-499
CrossRef30
H. Voller, W. Kamke, H. U. Klein, M. Block, R. Reibis, S. Treusch, K. Contzen, K. Wegscheider, . (2011) Clinical practice of defibrillator implantation after myocardial infarction: impact of implant time: results from the PreSCD II Registry. Europace 13:4, 499-508
CrossRef31
M. Santini, C. Pignalberi. (2011) Timing of defibrillator implant after acute myocardial infarction: what's new?. Europace 13:4, 455-457
CrossRef32
Mahmoud Houmsse, Veronica Franco, William T. Abraham. (2011) Epidemiology of Sudden Cardiac Death in Patients with Heart Failure. Heart Failure Clinics 7:2, 147-155
CrossRef33
Cynthia M. Tracy. (2011) Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction. Heart Rhythm 8:3, 401-402
CrossRef34
Jonathan P. Piccini, Sana M. Al-Khatib, Anne S. Hellkamp, Kevin J. Anstrom, Jeanne E. Poole, Daniel B. Mark, Kerry L. Lee, Gust H. Bardy. (2011) Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Heart Rhythm 8:3, 393-400
CrossRef35
A. Ghani, A. H. E. M. Maas, P. P. H. M. Delnoy, A. R. Ramdat Misier, J. P. Ottervanger, A. Elvan. (2010) Sex-Based Differences in Cardiac Arrhythmias, ICD Utilisation and Cardiac Resynchronisation Therapy. Netherlands Heart Journal
CrossRef36
Arturo J Martí-Carvajal, Mario Cruciani, Arturo J Martí-Carvajal. 2010. Pharmacological interventions for treating dyslipidemia in patients with HIV infection. .
CrossRef37
Peter Weeke, Fredrik Folke, Gunnar H. Gislason, Freddy K. Lippert, Jonas B. Olesen, Charlotte Andersson, Emil L. Fosbøl, Mette G. Charlot, Jørgen K. Kanters, Henrik E. Poulsen, Søren Loumann Nielsen, Lars Køber, Christian Torp-Pedersen. (2010) Pharmacotherapy and hospital admissions before out-of-hospital cardiac arrest: A nationwide study. Resuscitation 81:12, 1657-1663
CrossRef38
H.H. Klein, A. Krämer, B.M. Pieske, H.-J. Trappe, H. Vries. (2010) Fahreignung bei kardiovaskulären Erkrankungen. Der Kardiologe 4:6, 441-473
CrossRef39
D. A. M. J. Theuns, T. Smith, M. G. M. Hunink, G. H. Bardy, L. Jordaens. (2010) Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. Europace 12:11, 1564-1570
CrossRef40
Eric C. Stecker. (2010) Is there new hope for sudden cardiac death prevention early after myocardial infarction?. Heart Rhythm 7:11, 1598-1599
CrossRef41
M. Juhani Junttila, Petra Barthel, Robert J. Myerburg, Timo H. Mäkikallio, Axel Bauer, Kurt Ulm, Antti Kiviniemi, Mikko Tulppo, Juha S. Perkiömäki, Georg Schmidt, Heikki V. Huikuri. (2010) Sudden cardiac death after myocardial infarction in patients with type 2 diabetes. Heart Rhythm 7:10, 1396-1403
CrossRef42
Soo Hwa Jang, Tae Hee Han, In Koo Hwang, Seon Ah Park, Yong Geun Kwak, Jin Bong Park, Seong Kyu Han, Pan Dong Ryu, So Yeong Lee. (2010) Increased αB-crystallin in hypothalamic paraventricular nucleus of rats with myocardial infarction. Neuroscience Letters 484:2, 123-127
CrossRef43
Kei Nishiyama, Satoshi Shizuta, Takahiro Doi, Takeshi Morimoto, Takeshi Kimura. (2010) Sudden cardiac death after PCI and CABG in the bare-metal stent era: Incidence, prevalence, and predictors. International Journal of Cardiology 144:2, 263-266
CrossRef44
Jérémy Fauconnier, Jean-Luc Pasquié, Patrice Bideaux, Alain Lacampagne, Sylvain Richard. (2010) Cardiomyocytes hypertrophic status after myocardial infarction determines distinct types of arrhythmia: Role of the ryanodine receptor. Progress in Biophysics and Molecular Biology 103:1, 71-80
CrossRef45
Niloufar Tabatabaei, Stephen C. Hammill. (2010) Role of the Automatic Implantable Cardioverter Defibrillator in the Post-myocardial Infarction Patient. Current Cardiovascular Risk Reports 4:5, 321-326
CrossRef46
H. V. Huikuri. (2010) Timing of implantation of cardioverter-defibrillator after acute myocardial infarction. Europace 12:8, 1057-1058
CrossRef47
S. M. Al-Khatib, G. Hafley, K. L. Lee, A. E. Buxton. (2010) Relation between time from myocardial infarction to enrolment and patient outcomes in the Multicenter UnSustained Tachycardia Trial. Europace 12:8, 1112-1118
CrossRef48
Faisal Shamshad, Satish Kenchaiah, Peter V. Finn, Jordi Soler-Soler, John J.V. McMurray, Eric J. Velazquez, Aldo P. Maggioni, Robert M. Califf, Karl Swedberg, Lars Kober, Yuri Belenkov, Sergei Varshavsky, Marc A. Pfeffer, Scott D. Solomon. (2010) Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: The VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). American Heart Journal 160:1, 145-151
CrossRef49
Mina K. Chung, Steven J. Szymkiewicz, Mingyuan Shao, Edwin Zishiri, Mark J. Niebauer, Bruce D. Lindsay, Patrick J. Tchou. (2010) Aggregate National Experience With the Wearable Cardioverter-Defibrillator. Journal of the American College of Cardiology 56:3, 194-203
CrossRef50
Ralph J. Verdino. (2010) The Wearable Cardioverter-Defibrillator. Journal of the American College of Cardiology 56:3, 204-205
CrossRef51
Jeffrey J. Goldberger. (2010) The coin toss: Implications for risk stratification for sudden cardiac death. American Heart Journal 160:1, 3-7
CrossRef52
Arturo J Martí-Carvajal, Ricardo Hidalgo, Shrikant Bangdiwala, Arturo J Martí-Carvajal. 2010. Prophylactic lidocaine for myocardial infarction. .
CrossRef53
Judith E. Arnetz, Ulrika Winblad, Anna T. Höglund, Bertil Lindahl, Kalle Spångberg, Lars Wallentin, Yun Wang, Joel Ager, Bengt B. Arnetz. (2010) Is patient involvement during hospitalization for acute myocardial infarction associated with post-discharge treatment outcome? An exploratory study. Health Expectationsno-no
CrossRef54
C.W. Israel. (2010) ICD-Therapie zur Primärprävention des plötzlichen Herztods. Herzschrittmachertherapie + Elektrophysiologie 21:2, 102-108
CrossRef55
N.C. Ewertsen, G. Steinbeck, J. Senges, D. Andresen. (2010) ICD-Therapie zur Primärprävention. Herzschrittmachertherapie + Elektrophysiologie 21:2, 109-111
CrossRef56
D. Bänsch, G. Grönefeld. (2010) Der Patient mit chronischer Herzinsuffizienz. Herzschrittmachertherapie + Elektrophysiologie 21:2, 112-116
CrossRef57
Beata Sredniawa, Michal Mazurek, Radoslaw Lenarczyk, Oskar Kowalski, Jacek Kowalczyk, Zbigniew Kalarus. (2010) Early therapy following myocardial infarction: arguments for and against implantable cardioverter-defibrillators. Future Cardiology 6:3, 315-323
CrossRef58
Richard N Vest, Michael R Gold. (2010) Risk stratification of ventricular arrhythmias in patients with systolic heart failure. Current Opinion in Cardiology 25:3, 268-275
CrossRef59
Li-Ling Tan, Hwee-Bee Wong, Chin-Leng Poh, Mark Y. Chan, Swee-Chong Seow, Tiong-Cheng Yeo, Swee-Guan Teo, Shirley B.S. Ooi, Huay-Cheem Tan, Chi-Hang Lee. (2010) Utilisation of Emergency Medical Service Among Singapore Patients Presenting with ST-Segment Elevation Myocardial Infarction: Prevalence and Impact on Ischaemic Time. Internal Medicine Journalno-no
CrossRef60
Emile G Daoud, John D Hummel, Troy E Rhodes. (2010) Management of sudden cardiac death risk in the very early postmyocardial infarction period. Current Opinion in Cardiology1
CrossRef61
A. Selcuk Adabag, Russell V. Luepker, Véronique L. Roger, Bernard J. Gersh. (2010) Sudden cardiac death: epidemiology and risk factors. Nature Reviews Cardiology 7:4, 216-225
CrossRef62
HELMUT U. KLEIN, ULF MELTENDORF, SVEN REEK, JAN SMID, SEBASTIAN KUSS, IWONA CYGANKIEWICZ, CHRISTIAN JONS, STEVEN SZYMKIEWICZ, FRANK BUHTZ, ANKE WOLLBRUECK, WOJCIECH ZAREBA, ARTHUR J. MOSS. (2010) Bridging a Temporary High Risk of Sudden Arrhythmic Death. Experience with the Wearable Cardioverter Defibrillator (WCD). Pacing and Clinical Electrophysiology 33:3, 353-367
CrossRef63
J. P. Piccini, M. Zhang, K. Pieper, S. D. Solomon, S. M. Al-Khatib, F. Van de Werf, M. A. Pfeffer, J. J.V. McMurray, R. M. Califf, E. J. Velazquez. (2010) Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. European Heart Journal 31:2, 211-221
CrossRef64
JONATHAN P. PICCINI, SANA M. AL-KHATIB, EVAN R. MYERS, KEVIN J. ANSTROM, ALFRED E. BUXTON, ERIC D. PETERSON, GILLIAN D. SANDERS. (2010) Optimal Timing of Implantable Cardioverter-Defibrillator Implantation After Myocardial Infarction: A Decision Analysis. Journal of Cardiovascular Electrophysiology
CrossRef65
P. Pascale, J. Schlaepfer, M. Oddo, M.-D. Schaller, P. Vogt, M. Fromer. (2009) Ventricular arrhythmia in coronary artery disease: limits of a risk stratification strategy based on the ejection fraction alone and impact of infarct localization. Europace 11:12, 1639-1646
CrossRef66
Stavros Mountantonakis, Mathew D. Hutchinson. (2009) Who should receive an implantable cardioverter-defibrillator after myocardial infarction?. Current Heart Failure Reports 6:4, 236-244
CrossRef67
C. Adamopoulos, A. Ahmed, R. Fay, M. Angioi, G. Filippatos, J. Vincent, B. Pitt, F. Zannad, . (2009) Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. European Journal of Heart Failure 11:11, 1099-1105
CrossRef68
Jeffrey J. Goldberger, Rod Passman. (2009) Implantable Cardioverter-Defibrillator Therapy After Acute Myocardial Infarction. Journal of the American College of Cardiology 54:22, 2001-2005
CrossRef69
Gwenaelle Wernli, Wohaib Hasan, Aritra Bhattacherjee, Nico Rooijen, Peter G. Smith. (2009) Macrophage depletion suppresses sympathetic hyperinnervation following myocardial infarction. Basic Research in Cardiology 104:6, 681-693
CrossRef70
Garber, Alan M., Hlatky, Mark A., . (2009) The Confirmatory Trial in Comparative-Effectiveness Research. New England Journal of Medicine 361:15, 1498-1499
Full Text71
Steinbeck, Gerhard, Andresen, Dietrich, Seidl, Karlheinz, Brachmann, Johannes, Hoffmann, Ellen, Wojciechowski, Dariusz, Kornacewicz-Jach, Zdzisława, Sredniawa, Beata, Lupkovics, Géza, Hofgärtner, Franz, Lubinski, Andrzej, Rosenqvist, Mårten, Habets, Alphonsus, Wegscheider, Karl, Senges, Jochen, . (2009) Defibrillator Implantation Early after Myocardial Infarction. New England Journal of Medicine 361:15, 1427-1436
Full Text72
Neil E. I. Langlois. (2009) Sudden adult death. Forensic Science, Medicine, and Pathology 5:3, 210-232
CrossRef73
Andrew E. Epstein. (2009) Update on primary prevention implantable cardioverter-defibrillator therapy. Current Cardiology Reports 11:5, 335-342
CrossRef74
S. Genovesi, M. G. Valsecchi, E. Rossi, D. Pogliani, I. Acquistapace, V. De Cristofaro, A. Stella, A. Vincenti. (2009) Sudden death and associated factors in a historical cohort of chronic haemodialysis patients. Nephrology Dialysis Transplantation 24:8, 2529-2536
CrossRef75
Robert J. Myerburg, Vivek Reddy, Agustin Castellanos. (2009) Indications for Implantable Cardioverter-Defibrillators Based on Evidence and Judgment. Journal of the American College of Cardiology 54:9, 747-763
CrossRef76
Alfred E. Buxton. (2009) Risk stratification for sudden death in patients with coronary artery disease. Heart Rhythm 6:6, 836-847
CrossRef77
János Tomcsányi, Péter Bezzeg. (2009) Home ECG monitoring of high-risk post-myocardial infarction patients. Clinical and Experimental Medical Journal 3:2, 263-267
CrossRef78
Derek V. Exner. (2009) Noninvasive risk stratification after myocardial infarction: Rationale, current evidence and the need for definitive trials. Canadian Journal of Cardiology 25, 21A-27A
CrossRef79
János Tomcsányi, Péter Bezzeg. (2009) Otthoni EKG-monitorozás magas rizikójú posztinfarktusos betegeken. Orvosi Hetilap 150:21, 985-988
CrossRef80
Jeffrey J. Goldberger. (2009) Evidence-based analysis of risk factors for sudden cardiac death. Heart Rhythm 6:3, S2-S7
CrossRef81
Christina M. Holmgren, Britta M. Nyström, Thomas K. Karlsson, Johan D. Herlitz, Nils G. Edvardsson. (2009) Presumed arrhythmic death in consecutive survivors of acute myocardial infarction – implications for primary implantable cardioverter defibrillator implantation. Coronary Artery Disease 20:2, 155-162
CrossRef82
B. A. Koplan, W. G. Stevenson. (2009) Ventricular Tachycardia and Sudden Cardiac Death. Mayo Clinic Proceedings 84:3, 289-297
CrossRef83
Mithilesh Das. (2009) Indications for ICD and cardiac resynchronization therapy for prevention of sudden cardiac death. Expert Review of Cardiovascular Therapy 7:2, 181-195
CrossRef84
Jaydutt B. Patel, Bruce A. Koplan. (2009) ICD implantation in patients with ischemic left ventricular dysfunction. Current Treatment Options in Cardiovascular Medicine 11:1, 3-9
CrossRef85
Lance D. Wilson, Darwin Jeyaraj, Xiaoping Wan, Gregory S. Hoeker, Tamer H. Said, Matthew Gittinger, Kenneth R. Laurita, David S. Rosenbaum. (2009) Heart failure enhances susceptibility to arrhythmogenic cardiac alternans. Heart Rhythm 6:2, 251-259
CrossRef86
N. M. Hawkins, Z. Huang, K. S. Pieper, S. D. Solomon, L. Kober, E. J. Velazquez, K. Swedberg, M. A. Pfeffer, J. J.V. McMurray, A. P. Maggioni, . (2009) Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal of Heart Failure 11:3, 292-298
CrossRef87
Raymond Y. Kwong. (2009) Can Cardiac Magnetic Resonance Myocardial Scar Features Affect Treatment Decisions for Patients With Coronary Artery Disease and Heart Failure?
Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology.. JACC: Cardiovascular Imaging 2:1, 45-47
CrossRef88
Sofiene Rekik, Sabeur Mnif, Mohammed Sahnoun, Salma Krichen, Hanene Charfeddine, Imen Trabelsi, Faten Triki, Mourad Hentati, Samir Kammoun. (2009) Total absence of ST-segment resolution after failed thrombolysis is correlated with unfavorable short- and long-term outcomes despite successful rescue angioplasty. Journal of Electrocardiology 42:1, 73-78
CrossRef89
Myerburg, Robert J., . (2008) Implantable Cardioverter–Defibrillators after Myocardial Infarction. New England Journal of Medicine 359:21, 2245-2253
Full Text90
Rajesh Subbiah, Lorne J. Gula, George J. Klein, Allan C. Skanes, James White, Raymond Yee, Andrew D. Krahn. (2008) Workup of the Cardiac Arrest Survivor. Progress in Cardiovascular Diseases 51:3, 195-203
CrossRef91
Rüdiger Dissmann, Wolfram Kamke, Rona Reibis, Joachim Herbstleb, Karl Wegscheider, Heinz Völler. (2008) Prognostic impact of left bundle-branch block in the early stable phase after acute myocardial infarction. International Journal of Cardiology 130:3, 438-443
CrossRef92
Giuseppe Garcea, Mohammed Gouda, Christopher Hebbes, Seok Ling Ong, Christopher P. Neal, Ashley R. Dennison, David Paul Berry. (2008) Predictors of Severity and Survival in Acute Pancreatitis. Pancreas 37:3, e54-e61
CrossRef93
Jeffrey J. Goldberger, Michael E. Cain, Stefan H. Hohnloser, Alan H. Kadish, Bradley P. Knight, Michael S. Lauer, Barry J. Maron, Richard L. Page, Rod S. Passman, David Siscovick, William G. Stevenson, Douglas P. Zipes. (2008) American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. Heart Rhythm 5:10, e1-e21
CrossRef94
STEFAN H HOHNLOSER. (2008) Risk Stratification Using T-Wave Alternans: More Questions Waiting to be Answered. Journal of Cardiovascular Electrophysiology 19:10, 1043-1044
CrossRef95
P. Abrahamsson, J. Dobson, C. B. Granger, J. J.V. McMurray, E. L. Michelson, M. Pfeffer, S. Pocock, S. D. Solomon, S. Yusuf, K. Swedberg, . (2008) Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. European Heart Journal 30:3, 338-345
CrossRef96
Jeffrey J. Goldberger, Michael E. Cain, Stefan H. Hohnloser, Alan H. Kadish, Bradley P. Knight, Michael S. Lauer, Barry J. Maron, Richard L. Page, Rod S. Passman, David Siscovick, William G. Stevenson, Douglas P. Zipes. (2008) American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. Journal of the American College of Cardiology 52:14, 1179-1199
CrossRef97
Andrew E. Epstein. (2008) Benefits of the Implantable Cardioverter-Defibrillator. Journal of the American College of Cardiology 52:14, 1122-1127
CrossRef98
Roderick Tung, Peter Zimetbaum, Mark E. Josephson. (2008) A Critical Appraisal of Implantable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology 52:14, 1111-1121
CrossRef99
H. V. Huikuri, M.J. P. Raatikainen, R. Moerch-Joergensen, J. Hartikainen, V. Virtanen, J. Boland, O. Anttonen, N. Hoest, L. V.A. Boersma, E. S. Platou, M. D. Messier, P.-E. Bloch-Thomsen, . (2008) Prediction of fatal or near-fatal cardiac arrhythmia events in patients with depressed left ventricular function after an acute myocardial infarction. European Heart Journal 30:6, 689-698
CrossRef100
ALAWI A. ALSHEIKH-ALI, MICHAEL HOMER, PRASAD V. MADDUKURI, BENJAMIN KALSMITH, N. A. MARK ESTES, MARK S. LINK. (2008) Time-Dependence of Appropriate Implantable Defibrillator Therapy in Patients with Ischemic Cardiomyopathy. Journal of Cardiovascular Electrophysiology 19:8, 784-789
CrossRef101
BRETT FAULKNIER, DAVID T. HUANG, JAMES P. DAUBERT. (2008) Time Dependence of Arrhythmias in ICD Patients. Journal of Cardiovascular Electrophysiology 19:8, 790-793
CrossRef102
(2008) Home Automated Defibrillators after Myocardial Infarction. New England Journal of Medicine 359:5, 533-535
Full Text103
P. M. Spooner. (2008) Sudden cardiac death: influence of diabetes. Diabetes, Obesity and Metabolism 10:7, 523-532
CrossRef104
Rachel E. Anderson, Marc A. Pfeffer, Jens Jakob Thune, John J.V. McMurray, Robert M. Califf, Eric Velazquez, Harvey D. White, Jean L. Rouleau, Hicham Skali, Aldo Maggioni, Scott D. Solomon. (2008) High-risk myocardial infarction in the young: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. American Heart Journal 155:4, 706-711
CrossRef105
G. Ertl, J. Bauersachs, S. Frantz. (2008) Vom kardiovaskulären Risiko zum chronischen Herzversagen. Der Internist 49:4, 387-388
CrossRef106
Judith Hsia, Kathleen A. Jablonski, Madeline Murguia Rice, Marc S. Sabatine, Miguel Zabalgoitia, Aldo Maggioni, Thomas E. Cuddy, Michael J. Domanski, Nancy L. Geller, Greg Flaker, Scott Solomon, Torbjørn Omland, Jean L. Rouleau. (2008) Sudden Cardiac Death in Patients With Stable Coronary Artery Disease and Preserved Left Ventricular Systolic Function. The American Journal of Cardiology 101:4, 457-461
CrossRef107
Kenneth R. Laurita, David S. Rosenbaum. (2008) Mechanisms and potential therapeutic targets for ventricular arrhythmias associated with impaired cardiac calcium cycling. Journal of Molecular and Cellular Cardiology 44:1, 31-43
CrossRef108
James J.H. Chong, Anand N. Ganesan, Vicki Eipper, Pramesh Kovoor. (2008) Comparison of Left Ventricular Ejection Fraction and Inducible Ventricular Tachycardia in ST-Elevation Myocardial Infarction Treated by Primary Angioplasty Versus Thrombolysis. The American Journal of Cardiology 101:2, 153-157
CrossRef109
Kevin L. Thomas, Sana M. Al-Khatib, Yuliya Lokhnygina, Scott D. Solomon, Lars Kober, John J.V. McMurray, Robert M. Califf, Eric J. Velazquez. (2008) Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. American Heart Journal 155:1, 87-93
CrossRef110
Wilhelm Roell, Thorsten Lewalter, Philipp Sasse, Yvonne N. Tallini, Bum-Rak Choi, Martin Breitbach, Robert Doran, Ulrich M. Becher, Seong-Min Hwang, Toktam Bostani, Julia von Maltzahn, Andreas Hofmann, Shaun Reining, Britta Eiberger, Bethann Gabris, Alexander Pfeifer, Armin Welz, Klaus Willecke, Guy Salama, Jan W. Schrickel, Michael I. Kotlikoff, Bernd K. Fleischmann. (2007) Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia. Nature 450:7171, 819-824
CrossRef111
Derek V. Exner, Katherine M. Kavanagh, Michael P. Slawnych, L. Brent Mitchell, Darlene Ramadan, Sandeep G. Aggarwal, Catherine Noullett, Allie Van Schaik, Ryan T. Mitchell, Mariko A. Shibata, Sajad Gulamhussein, James McMeekin, Wayne Tymchak, Gregory Schnell, Anne M. Gillis, Robert S. Sheldon, Gordon H. Fick, Henry J. Duff. (2007) Noninvasive Risk Assessment Early After a Myocardial Infarction. Journal of the American College of Cardiology 50:24, 2275-2284
CrossRef112
Maryse Palardy, Anique Ducharme, Eileen O’Meara. (2007) Inhibiting the renin-angiotensin system with ACE inhibitors or ARBs after MI. Current Heart Failure Reports 4:4, 190-197
CrossRef113
Anil Verma, Scott D. Solomon. (2007) Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist. Current Heart Failure Reports 4:4, 183-189
CrossRef114
Jan Paul Ottervanger, Anand R. Ramdat Misier, Jan-Henk E. Dambrink, Menko-Jan de Boer, Jan C.A. Hoorntje, A.T. Marcel Gosselink, Harry Suryapranata, Stoffer Reiffers, Arnoud W.J. van ‘t Hof. (2007) Mortality in Patients With Left Ventricular Ejection Fraction ≤30% After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. The American Journal of Cardiology 100:5, 793-797
CrossRef115
Mintu Turakhia, Zian H. Tseng. (2007) Sudden Cardiac Death: Epidemiology, Mechanisms, and Therapy. Current Problems in Cardiology 32:9, 501-546
CrossRef116
Mithilesh K. Das, Rajdeep Gaitonde, John M. Miller. (2007) Indications for implantable cardioverter defibrillator use for primary prevention of sudden cardiac death. Current Cardiology Reports 9:5, 371-380
CrossRef117
Dan Hu, Sami Viskin, Antonio Oliva, Tabitha Carrier, Jonathan M. Cordeiro, Hector Barajas-Martinez, Yuesheng Wu, Elena Burashnikov, Serge Sicouri, Ramon Brugada, Rafael Rosso, Alejandra Guerchicoff, Guido D. Pollevick, Charles Antzelevitch. (2007) Novel mutation in the SCN5A gene associated with arrhythmic storm development during acute myocardial infarction. Heart Rhythm 4:8, 1072-1080
CrossRef118
J. Hollenberg, J. Lindqvist, M. Ringh, J. Engdahl, K. Bohm, M. Rosenqvist, L. Svensson. (2007) An evaluation of post-resuscitation care as a possible explanation of a difference in survival after out-of-hospital cardiac arrest. Resuscitation 74:2, 242-252
CrossRef119
Jacob A. Udell, David N. Juurlink, Alexander Kopp, Douglas S. Lee, Jack V. Tu, Muhammad M. Mamdani. (2007) Inequitable distribution of implantable cardioverter defibrillators in Ontario. International Journal of Technology Assessment in Health Care 23:03,
CrossRef120
Salvatore Rosanio, Ernst R. Schwarz, Antonio Vitarelli, Ignatius Gerardo E. Zarraga, Sanjay Kunapuli, David L. Ware, Yochai Birnbaum, Enrique Tuero, Barry F. Uretsky. (2007) Sudden death prophylaxis in heart failure. International Journal of Cardiology 119:3, 291-296
CrossRef121
Sana M. Al-Khatib, Gillian D. Sanders, J. Thomas Bigger, Alfred E. Buxton, Robert M. Califf, Mark Carlson, Anne Curtis, Jeptha Curtis, Eric Fain, Bernard J. Gersh, Michael R. Gold, Ali Haghighi-Mood, Stephen C. Hammill, Jeff Healey, Mark Hlatky, Stefan Hohnloser, Raymond J. Kim, Kerry Lee, Daniel Mark, Marcus Mianulli, Brent Mitchell, Eric N. Prystowsky, Joseph Smith, David Steinhaus, Wojciech Zareba. (2007) Preventing tomorrow's sudden cardiac death today. American Heart Journal 153:6, 941-950
CrossRef122
Malin Lorentzon, Truls Råmunddal, Entela Bollano, Bassam Soussi, Finn Waagstein, Elmir Omerovic. (2007) In Vivo Effects of Myocardial Creatine Depletion on Left Ventricular Function, Morphology, and Energy Metabolism—Consequences in Acute Myocardial Infarction. Journal of Cardiac Failure 13:3, 230-237
CrossRef123
Iwan C. C. Horst, Adriaan A. Voors, Dirk J. Veldhuisen. (2007) Treatment of heart failure with ACE inhibitors and beta-blockers. Clinical Research in Cardiology 96:4, 193-195
CrossRef124
Kent Stephenson, Hicham Skali, John J.V. McMurray, Eric J. Velazquez, Philip G. Aylward, Lars Kober, Frans Van de Werf, Harvey D. White, Karen S. Pieper, Robert M. Califf, Scott D. Solomon, Marc A. Pfeffer. (2007) Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: The VALIANT experience. Heart Rhythm 4:3, 308-313
CrossRef125
Andrew E. Epstein, Christina A. Baessler, Anne B. Curtis, N.A. Mark Estes, Bernard J. Gersh, Blair Grubb, L. Brent Mitchell. (2007) Addendum to “Personal and Public Safety Issues Related to Arrhythmias that May Affect Consciousness: Implications for Regulation and Physician Recommendations: A Medical/Scientific Statement from the American Heart Association and the North American Society of Pacing and Electrophysiology”. Heart Rhythm 4:3, 386-393
CrossRef126
Mihai Gheorghiade, Gregg C. Fonarow. (2007) Management of Post-Myocardial Infarction Patients with Left Ventricular Systolic Dysfunction. The American Journal of Medicine 120:2, 109-120
CrossRef127
Eric Larose, Peter Ganz, H. Glenn Reynolds, Sharmila Dorbala, Marcelo F. Di Carli, Kenneth A. Brown, Raymond Y. Kwong. (2007) Right Ventricular Dysfunction Assessed by Cardiovascular Magnetic Resonance Imaging Predicts Poor Prognosis Late After Myocardial Infarction. Journal of the American College of Cardiology 49:8, 855-862
CrossRef128
Marc A. Pfeffer. 2007. Myocardial Infarction: Risks and Hope. , 211-217.
CrossRef129
Raban V. Jeger, Susan F. Assmann, Loran Yehudai, Krishnan Ramanathan, Michael E. Farkouh, Judith S. Hochman. (2007) Causes of death and re‐hospitalization in cardiogenic shock. Acute Cardiac Care 9:1, 25-33
CrossRef130
G. Ertl, C. E. Angermann. (2007) Therapie der chronischen Linksherzinsuffizienz. Der Internist 48:1, 59-68
CrossRef131
Rishi Sukhija, Vimal Mehta, Marino Leonardi, Jawahar L. Mehta. (2007) Implantable cardioverter defibrillators for prevention of sudden cardiac Death. Clinical Cardiology 30:1, 3-8
CrossRef132
Piero Anversa, Konrad Urbanek, Claudia Bearzi, Antonella De Angelis, Marcello Rota. 2007. Cardiac Stem Cells and the Failing Heart. , 201-210.
CrossRef133
Takanori Ikeda, Hideaki Yoshino, Kaoru Sugi, Kaoru Tanno, Hiroki Shimizu, Jun Watanabe, Yuji Kasamaki, Akihiro Yoshida, Takao Kato. (2006) Predictive Value of Microvolt T-Wave Alternans for Sudden Cardiac Death in Patients With Preserved Cardiac Function After Acute Myocardial Infarction. Journal of the American College of Cardiology 48:11, 2268-2274
CrossRef134
Wohaib Hasan, Abdi Jama, Timothy Donohue, Gwenaelle Wernli, Gregory Onyszchuk, Baraa Al-Hafez, Mehmet Bilgen, Peter G. Smith. (2006) Sympathetic hyperinnervation and inflammatory cell NGF synthesis following myocardial infarction in rats. Brain Research 1124:1, 142-154
CrossRef135
Jeffery T. Fletcher, Nicole Graf, Anthony Scarman, Hamda Saleh, Stephen I. Alexander. (2006) Nephrotoxicity with cyclooxygenase 2 inhibitor use in children. Pediatric Nephrology 21:12, 1893-1897
CrossRef136
Bertram Pitt, Roberto Ferrari, Mihai Gheorghiade, Dirk J. van Veldhuisen, Henry Krum, John McMurray, Jose Lopez-Sendon. (2006) Aldosterone blockade in post-acute myocardial infarction heart failure. Clinical Cardiology 29:10, 434-438
CrossRef137
Douglas P. Zipes, A. John Camm, Martin Borggrefe, Alfred E. Buxton, Bernard Chaitman, Martin Fromer, Gabriel Gregoratos, George Klein, Arthur J. Moss, Robert J. Myerburg, Silvia G. Priori, Miguel A. Quinones, Dan M. Roden, Michael J. Silka, Cynthia Tracy, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Elliott M. Antman, Jeffrey L. Anderson, Sharon A. Hunt, Jonathan L. Halperin, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel, Silvia G. Priori, Jean-Jacques Blanc, Andrzej Budaj, A. John Camm, Veronica Dean, Jaap W. Deckers, Catherine Despres, Kenneth Dickstein, John Lekakis, Keith McGregor, Marco Metra, Joao Morais, Ady Osterspey, Juan Luis Tamargo, José Luis Zamorano. (2006) ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology 48:5, e247-e346
CrossRef138
Daniel Vallbohmer, Steven R. DeMeester, Daniel S. Oh, Farzaneh Banki, Hidekazu Kuramochi, Daisuke Shimizu, Jeffrey A. Hagen, Kathleen D. Danenberg, Peter V. Danenberg, Parakrama T. Chandrasoma, Jeffrey H. Peters, Tom R. DeMeester. (2006) Antireflux Surgery Normalizes Cyclooxygenase-2 Expression in Squamous Epithelium of the Distal Esophagus. The American Journal of Gastroenterology 101:7, 1458-1466
CrossRef139
Fred Kusumoto, Nora Goldschlager. (2006) Implantable cardiac arrhythmia devices-Part II: Implantable cardioverter defibrillators and implantable loop recorders. Clinical Cardiology 29:6, 237-242
CrossRef140
Oscar Bernal, Concepción Moro. (2006) Arritmias cardiacas en la mujer. Revista Española de Cardiología 59:6, 609-618
CrossRef141
Sami Viskin. (2006) Prediction versus prevention of sudden cardiac death. The Lancet 367:9523, 1639-1641
CrossRef142
Rhian M. Touyz. (2006) Highlights and summary of the 2006 Canadian Hypertension Education Program recommendations. Canadian Journal of Cardiology 22:7, 565-571
CrossRef143
Barry M. Massie, Thomas Force. (2006) The Year in Heart Failure 2005. Journal of Cardiac Failure 12:1, 1-9
CrossRef144
Steven P. Schulman, Tracey K. Hartmann, Romergryko G. Geocadin. (2006) Intensive Care After Resuscitation from Cardiac Arrest: A Focus on Heart and Brain Injury. Neurologic Clinics 24:1, 41-59
CrossRef145
Alfredo Bardají, Joaquín Alonso, Xavier García-Moll, Héctor Bueno. (2006) Actualización en cardiopatía isquémica 2005. Revista Española de Cardiología 59, 3-19
CrossRef146
A.L. Waldo. (2006) Sudden Death in Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. Yearbook of Cardiology 2006, 442-443
CrossRef147
José Azpitarte. (2006) Profilaxis primaria con desfibrilador-cardioversor implantable en la insuficiencia cardiaca: un punto de vista clínico. Revista Española de Cardiología 59, 10-22
CrossRef148
Kevin L. Thomas, Eric J. Velazquez. (2005) Therapies to prevent heart failure post-myocardial infarction. Current Heart Failure Reports 2:4, 174-182
CrossRef149
Philippe Ravaud, Florence Tubach. (2005) Methodology of therapeutic trials: lessons from the late evidence of the cardiovascular toxicity of some coxibs. Joint Bone Spine 72:6, 451-455
CrossRef150
Hendrik Bonnemeier, Ulrich Sch??fer. (2005) Neurocardiology: Antifibrillatory effects of heart-brain interactions after myocardial reperfusion*. Critical Care Medicine 33:11, 2708-2709
CrossRef151
(2005) Sudden Death in Patients with Myocardial Infarction. New England Journal of Medicine 353:12, 1294-1297
Full Text152
P. J. M. M. Toll. (2005) Plotseling overlijden na een hartinfarct. MFM 43:8, 222-222
CrossRef153
Buxton, Alfred E., . (2005) Sudden Death after Myocardial Infarction — Who Needs Prophylaxis, and When?. New England Journal of Medicine 352:25, 2638-2640
Full Text154
Katherine F Croom, Greg L Plosker. (2005) Eplerenone. PharmacoEconomics 23:10, 1057-1072
CrossRef
- Letters
